Soleno Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 38.99 million compared to USD 24.07 million a year ago. Basic loss per share from continuing operations was USD 2.36 compared to USD 2.87 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.2 USD | -0.01% | -5.04% | +12.40% |
13/05 | Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating | MT |
10/05 | Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.40% | 1.65B | |
+7.70% | 113B | |
+11.06% | 106B | |
+0.41% | 22.27B | |
-11.95% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.74% | 17.24B | |
+6.89% | 14.29B | |
+35.85% | 12.52B |
- Stock Market
- Equities
- SLNO Stock
- News Soleno Therapeutics, Inc.
- Soleno Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023